Document is current
Any future updates will be listed below
-
Authors
Stanley, Ian H.
Chu, Carol
Gildea, Sarah M.
Hwang, Irving H.
King, Andrew J.
Kennedy, Chris J. http://orcid.org/0000-0001-7444-2766
Luedtke, Alex
Marx, Brian P.
O’Brien, Robert
Petukhova, Maria V.
Sampson, Nancy A.
Vogt, Dawne
Stein, Murray B. http://orcid.org/0000-0001-9564-2871
Ursano, Robert J. http://orcid.org/0000-0002-1861-9173
Kessler, Ronald C. http://orcid.org/0000-0003-4831-2305
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01MH087981, T32MH019836, U01MH087981, U01MH087981)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Defense (HU00011520004)
- License Information
-
More Information
Article History
Received: 23 August 2021
Revised: 3 December 2021
Accepted: 9 December 2021
First Online: 20 January 2022
Competing interests
: In the past 3 years, RCK was a consultant for Datastat, Inc., Holmusk, RallyPoint Networks, Inc., and Sage Therapeutics. He has stock options in Mirah, PYM, and Roga Sciences. In the past 3 years MBS received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, Boehringer Ingelheim, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, Engrail Therapeutics, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech. MBS has stock options in Oxeia Biopharmaceuticals and EpiVario. He is paid for his editorial work on <i>Depression and Anxiety</i> (Editor-in-Chief), <i>Biological Psychiatry</i> (Deputy Editor), and <i>UpToDate</i> (Co-Editor-in-Chief for Psychiatry). The other authors declare that they have no conflict of interest.
